Jack A. Khattar - 01 Feb 2023 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Role: President, CEO, Director
Signature: /s/ Timothy C. Dec, as attorney-in-fact
Issuer symbol: SUPN
Transactions as of: 01 Feb 2023
Transactions value $: -$7,841
Form type: 4
Filing time: 03 Feb 2023, 16:00:49 UTC
Previous filing: 02 Feb 2023
Next filing: 06 Feb 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SUPN	Common Stock	Options Exercise	$4.76K	+498	+0.06%	$9.56	795K	01 Feb 2023	Direct	F1
transaction	SUPN	Common Stock	Sale	-$12.6K	-300	-0.04%	$42.01	795K	01 Feb 2023	Direct	F1, F2
holding	SUPN	Common Stock						1.05M	01 Feb 2023	By the KBT Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SUPN	Employee Stock Option (Right to Buy)	Options Exercise	$0	-498	-1.03%	$0.00	47.9K	01 Feb 2023	Common Stock	498	$9.56	Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.02, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F3	The options vested in four equal annual installments beginning on January 23, 2015.